IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 12.6 SEK -1.95%
Market Cap: 652.5m SEK
Have any thoughts about
IRLAB Therapeutics AB?
Write Note

IRLAB Therapeutics AB
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

IRLAB Therapeutics AB
Cash & Cash Equivalents Peer Comparison

Comparables:
CALTX
CAMX
S
SECARE
MOB
I
FLERIE

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
IRLAB Therapeutics AB
STO:IRLAB A
Cash & Cash Equivalents
kr111.3m
CAGR 3-Years
-26%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Cash & Cash Equivalents
kr797.3m
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Cash & Cash Equivalents
kr2.6B
CAGR 3-Years
83%
CAGR 5-Years
55%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Cash & Cash Equivalents
kr170m
CAGR 3-Years
-49%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Cash & Cash Equivalents
kr60.6m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Cash & Cash Equivalents
kr882.2m
CAGR 3-Years
23%
CAGR 5-Years
77%
CAGR 10-Years
N/A

See Also

What is IRLAB Therapeutics AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
111.3m SEK

Based on the financial report for Dec 31, 2023, IRLAB Therapeutics AB's Cash & Cash Equivalents amounts to 111.3m SEK.

What is IRLAB Therapeutics AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-4%

Over the last year, the Cash & Cash Equivalents growth was -56%. The average annual Cash & Cash Equivalents growth rates for IRLAB Therapeutics AB have been -26% over the past three years , -4% over the past five years .

Back to Top